Disease-Specific as Well as Generic Quality of Life Is Widely Impacted in Autoimmune Hypothyroidism and Improves during the First Six Months of Levothyroxine Therapy
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Hypothyroidism is often diagnosed, and subsequently treated, due to health-related quality of life (HRQL) issues. However, HRQL following treatment has never previously been assessed in longitudinal descriptive studies using validated instruments. OBJECTIVE: To investigate disease-specific (ThyPRO) and generic (SF-36) HRQL, following levothyroxine therapy in patients with hypothyroidism due to autoimmune thyroiditis. METHODS: This prospective cohort study was set at endocrine outpatient clinics at two Danish university hospitals. Seventy-eight consecutive patients were enrolled and completed HRQL questionnaires before, six weeks, and six months after initiation of levothyroxine therapy. Normative ThyPRO (n = 739) and SF-36 (n = 6,638) data were available for comparison and changes in HRQL following treatment were estimated and quantified. RESULTS: Prior to treatment, all ThyPRO scales were significantly impacted (p<0.0001), compared to the general population sample. The same was observed for seven of eight SF-36 scales, the exception being Bodily Pain. Tiredness (ThyPRO) and Vitality (SF-36) were the most markedly impacted scales. After six weeks of treatment, nine of thirteen ThyPRO scales had significantly improved. ThyPRO improvements were consistent at six months, where five of eight SF-36 scales had also significantly improved, but deficits persisted for a subset of both ThyPRO and SF-36 scales. CONCLUSIONS: In this population of hypothyroid patients, HRQL was widely affected before treatment, with tiredness as the cardinal impairment according to both ThyPRO and SF-36. Many aspects of HRQL improved during the first six months of LT4 therapy, but full recovery was not obtained. Our results may help clinicians inform patients about expected clinical treatment effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A ThyPRO Composite scale score of 32 or TSQ >4 has been shown to represent a score that signifies a worse QoL, which is sufficiently above the mean score in patients with hypothyroidism (32).”
From Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design (2023) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When patients with hypothyroidism were compared with the general population, tiredness was one of the parameters that showed the most difference between the populations, with a large effect size (66).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“In an uncontrolled prospective study of the initiation of LT4 therapy for mild hypothyroidism (TSH values 5.5–12.2 mIU/L), it was also one of the scales that showed the most improvement with treatment (66).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“The cognitive complaints scale, although different from the general population, did not improve significantly with 6 months of LT4 treatment.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“When patients with hypothyroidism were compared with the general population, tiredness was one of the parameters that showed the most difference between the populations, with a large effect size [66].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [66]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033 · cited 1×
“Measurement properties have been well-described for the most widely used generic instrument, SF-36 [11,12], while some currently available disease-specific instruments (4,6) have undergone initial validation in hypothyroid patients [6,13,14].”
MethodCohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Measuring Health-Related Quality of Life
Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00009 · Cited by 3,958
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824 · cited 1×
“This is well in line with the Colorado thyroid disease prevalence study, where 40% of patients taking thyroid medication had abnormal TSH levels [30].”
ResultThe impact of patient-centered care on outcomes.
Stewart, M., Brown, J. B., DONNER, A. P., McWhinney, I. R., Oates, J., Weston, W. W., & Jordan, J. (2000) · PubMed · Cited by 2,508
Patient reported outcome measures could help transform healthcare
Black, N. (2013) · BMJ · doi:10.1136/bmj.f167 · Cited by 1,960
Biological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,272 · cited 1×
“HRQL assessment could do so by contributing, in a positive manner, to the overall therapeutic context [37].”
Background
Research works printed but not linked: 1
- Ware JE Jr., Kosinski M, Bjorner JB, Maruish M. 2007 SF-36 Health Survey. Manual and Interpretation Guide 2nd edition, QualityMetric Incorporated, Lincoln, RI.
Cited by
Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism
Stott, D. J., Rodondi, N., Kearney, P. M., Ford, I., Westendorp, R. G. J., Mooijaart, S. P., Sattar, N., Aubert, C. E., Aujesky, D., Bauer, D. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1603825 · Cited by 490
Self-citationEndocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Chaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288
Self-citationJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
“When patients with hypothyroidism were compared with the general population, tiredness was one of the parameters that showed the most difference between the populations, with a large effect size (66).”
InfluentialSelf-citationLillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2018) · Thyroid · doi:10.1089/thy.2017.0517 · Cited by 150
“H ypothyroidism has been linked to cardiovascular disorders (1–3) and psychiatric diseases (4), and is associated with impaired quality of life (5), increased risk of disability pension, and loss of labor market income (6).”
Self-citationPrimary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Self-citationMooijaart, S. P., Du Puy, R. S., Stott, D. J., Kearney, P. M., Rodondi, N., Westendorp, R. G. J., den Elzen, W. P. J., Postmus, I., Poortvliet, R. K. E., van Heemst, D., et al. (2019) · JAMA · doi:10.1001/jama.2019.17274 · Cited by 121
Self-citationThyroid hormone therapy for hypothyroidism
Biondi, B., & Cooper, D. S. (2019) · Endocrine · doi:10.1007/s12020-019-02023-7 · Cited by 119
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0006 · Cited by 100
Self-citationMitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81
Self-citationHypothyroidism and Depression: A Narrative Review
Nuguru, S. P., Rachakonda, S., Sripathi, S., Khan, M. I., Patel, N., & Meda, R. T. (2022) · Cureus · doi:10.7759/cureus.28201 · Cited by 148
“Several aspects of HRQL improved throughout the first six months of LT4 therapy, albeit complete recovery was not achieved [37].”
BackgroundJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationWinther, K. H., Wichman, J. E. M., Bonnema, S. J., & Hegedűs, L. D. (2016) · Endocrine · doi:10.1007/s12020-016-1098-z · Cited by 88
“By assessment with this instrument we have demonstrated widely impaired HRQL, that is not normalized following six months of LT4 treatment [49].”
BackgroundSelf-citationCohen, B. M., Sommer, B. R., & Vuckovic, A. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17080949 · Cited by 83
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
Djurovic, M. N., Pereira, A. M., Smit, J. W. A., Vasović, O., Damjanovic, S. S., Jemuovic, Z., Pavlović, D. M., Miljić, D., Pekić, S., Stojanović, M., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1649-6 · Cited by 83
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00364 · Cited by 69
“First, this leaves patients frequently dissatisfied, because their quality of life is not generally restored with LT4 treatment to the same level seen in healthy persons despite their TSH concentrations being within the reference range (29).”
BackgroundResultPerros, P., Van Der Feltz‐Cornelis, C., Papini, E., Nagy, E. V., Weetman, A. P., & Hegedüs, L. (2023) · Clinical Endocrinology · doi:10.1111/cen.14473 · Cited by 65
Self-citationNew Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?
Nagy, E. V., Perros, P., Papini, E., Katko, M., & Hegedüs, L. (2021) · Thyroid · doi:10.1089/thy.2020.0515 · Cited by 63
“While biochemical euthyroidism (normal serum thyrotropin [TSH]) can be achieved in patients treated with levothyroxine (LT4), quality of life (QoL) may not be restored (8,9).”
Self-citationYalçın, M. M., Altınova, A. E., Cavnar, B., Bolayır, B., Aktürk, M., Arslan, E., Özkan, Ç., Çakır, N., & Törüner, F. B. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0418 · Cited by 66
Levothyroxine therapy in elderly patients with hypothyroidism
Effraimidis, G., Watt, T., & Feldt-Rasmussen, U. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.641560 · Cited by 60
“However, there is no reliable laboratory index of peripheral thyroid hormone action, but some tests (27, 60), including sex steroid- binding globulin, serum ferritin, serum angiotensin- converting enzyme, as well as oxygen consumption (resting energy expenditure), systolic time interval, and cardiac contractility (61,…”
BackgroundSelf-citationBrain Fog in Hypothyroidism: What Is It, How Is It Measured, and What Can Be Done About It
Samuels, M. H., & Bernstein, L. J. (2022) · Thyroid · doi:10.1089/thy.2022.0139 · Cited by 64
Relational Stability in the Expression of Normality, Variation, and Control of Thyroid Function
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00142 · Cited by 48
Abbott, R. D., Sadowski, A., & Alt, A. G. (2019) · Cureus · doi:10.7759/cureus.4556 · Cited by 64
“When examining the data from the 58 participants completing the six-month study, it should be noted that the increases in these three domains ranged from only 3%-8%, correlating to a minimal effect size as well as a potentially insignificant change in clinical status [3].”
BackgroundMethodInfluentialMartino, G., Caputo, A., Vicario, C. M., Feldt‐Rasmussen, U., Watt, T., Quattropani, M. C. A., Benvenga, S., & Vita, R. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.667237 · Cited by 79
“Hypothyroidism is associated with psychopathological disturbances, such as depression, anxiety, and even poor HRQoL (Crisanti et al., 2001; Cooper and Biondi, 2012; Vita et al., 2013; Winther et al., 2016).”
BackgroundSelf-citationIndividualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Drugs in Context · doi:10.7573/dic.212597 · Cited by 41
Li, J., Huang, Q., Sun, S., Zhou, K., Wang, X., Pan, K., Zhang, Y., Wang, Y., Han, Q., Si, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-78938-7 · Cited by 68
Persistent hypothyroid symptoms in a patient with a normal thyroid stimulating hormone level
Jonklaas, J. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000355 · Cited by 38
Riis, K. R., Frølich, J. S., Hegedüs, L., Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Bonnema, S. J. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01555-y · Cited by 37
“Some patients suffering from thyroid failure have persistent symptoms despite adequate thyroid hormone replacement therapy with LT4 [8].”
Self-citationIs selenium supplementation in autoimmune thyroid diseases justified?
Winther, K. H., Bonnema, S. J., & Hegedüs, L. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000356 · Cited by 36
Self-citationTime for a reassessment of the treatment of hypothyroidism
Midgley, J. E. M., Toft, A. D., Larisch, R., Dietrich, J. W., & Hoermann, R. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0365-4 · Cited by 36
Brix, T. H., Ferløv-Schwensen, C., Thvilum, M., & Hegedűs, L. D. (2019) · Endocrine · doi:10.1007/s12020-019-01946-5 · Cited by 34
Self-citationde Montmollin, M., Feller, M., Beglinger, S., McConnachie, A., Aujesky, D., Collet, T., Ford, I., Gussekloo, J., Kearney, P. M., Carthy, V. J. C. M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3193 · Cited by 42
“Moreover, compared with a previous trial of 78 participants with subclinical (n = 66) and overt (n = 12) hypothyroidism (19), our subgroup of patients with high Hypothyroid Symptoms scores also had a much higher mean Hypothyroid Symptoms score (45 vs.”
BackgroundResultSelf-citationDetermining minimal important change for the thyroid related quality of life questionnaire ThyPRO
Nordqvist, S. F., Boesen, V. B., Rasmussen, Å. K., Feldt-Rasmussen, U., Hegedüs, L., Bonnema, S. J., Cramon, P. K., Watt, T., Groenvold, M., & Bjorner, J. B. (2021) · Endocrine Connections · doi:10.1530/ec-21-0026 · Cited by 31
Self-citationMorón-Díaz, M., Saavedra, P., Alberiche-Ruano, M. P., Rodríguez-Pérez, C. A., López-Plasencia, Y., Marrero, D., González-Lleó, A. M., & Boronat, M. (2020) · Endocrine · doi:10.1007/s12020-020-02449-4 · Cited by 33
Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?
Michaelsson, L. F., la Cour, J. L., Medici, B. B., Watt, T., Faber, J., & Nygaard, B. (2018) · European Thyroid Journal · doi:10.1159/000490383 · Cited by 30
Self-citationLocal symptoms of Hashimoto’s thyroiditis: A systematic review
Yuan, J., Qi, S., Zhang, X., Lai, H., Li, X., Xiaoheng, C., Li, Z., Yao, S., & Ding, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1076793 · Cited by 39
“0 (34-81) 0/25 Hypothyroidism (22), unclear (3) 33.”
Larisch, R., Midgley, J., Dietrich, J. W., & Hoermann, R. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-125064 · Cited by 30
Nunes, C. S. A., Maes, M. H. J., Roomruangwong, C., Moraes, J. B., Bonifácio, K. L., Vargas, H. O., Barbosa, D. S., Anderson, G., de Melo, L. G. P., Drozdstoj, S., et al. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12918 · Cited by 30
Sheikh, A., Mawani, M., & Mahar, S. A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0038 · Cited by 32
“Some studies have shown that the quality of life scores improve in those who are adequately replaced with thyroid hormone but usually stay lesser than their counterparts who do not have any degree of hypothyroidism (20-22).”
BackgroundApplying PRO Reference Values to Communicate Clinically Relevant Information at the Point-of-care
Jensen, R. E., & Bjørner, J. B. (2019) · Medical Care · doi:10.1097/mlr.0000000000001113 · Cited by 25
Impairment of health-related quality of life among Indian patients with hypothyroidism
Shivaprasad, C., Rakesh, B., Kolly, A., Annie, P., Amit, G., & Dwarakanath, C. S. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_702_17 · Cited by 44
Larsen, C. B., Winther, K. H., Cramon, P. K., Rasmussen, Å. K., Feldt‐Rasmussen, U., Knudsen, N. J., Bjørner, J. B., Schomburg, L., Demircan, K., Chillon, T. S., et al. (2024) · European Thyroid Journal · doi:10.1530/etj-23-0175 · Cited by 42
Self-citationAdvances in applied homeostatic modelling of the relationship between thyrotropin and free thyroxine
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. C. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187232 · Cited by 24
Borson‐Chazot, F., Terra, J., Goichot, B., & Caron, P. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071386 · Cited by 37
“Winther [13] PLoS One 2016 QoL in newly treated patients Prospective cohort study Denmark (2) Hypothyroidism due to autoimmune thyroiditis (n = 78) SF-36 and ThyPRO (primary outcomes) ↑ in LT4-treated patients”
BackgroundResultVardarli, I., Brandenburg, T., Hegedüs, L., Attanasio, R., Nagy, E., Papini, E., Perros, P., Weidemann, F., Herrmann, K., & Führer, D. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1832-0644 · Cited by 24
“Thyroid guidelines uniformly favor LT4 as standard therapy [12]; however, some patients with thyroid failure have persistent symp toms despite adequate thyroid hormone replacement therapy with LT4 [9].”
BackgroundSelf-citationThe importance of gluten exclusion in the management of Hashimoto’s thyroiditis
Ihnatowicz, P., Wątor, P., & Drywień, M. E. (2021) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/136523 · Cited by 29
“It is known that the quality of life of HT patients is reduced what might remain even after levothyroxine therapy [98].”
BackgroundPerros, P., Hegedűs, L. D., Nagy, E. V., Papini, E., Hay, H. A., Abad-Madroñero, J., Tallett, A. J., Bilas, M., Lakwijk, P., & Poots, A. J. (2022) · Thyroid · doi:10.1089/thy.2022.0324 · Cited by 30
Self-citationEvaluating health outcomes in the treatment of hypothyroidism
Ettleson, M. D., & Papaleontiou, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1026262 · Cited by 34
The interrelation between hypothyroidism and glaucoma: a critical review and meta‐analyses
Thvilum, M., Brandt, F., Brix, T. H., & Hegedűs, L. D. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13412 · Cited by 24
“Despite treatment, quality of life is affected, even long after euthyroidism has been restored (Watt et al. 2006; Winther et al. 2016).”
BackgroundSelf-citationFunctional and Symptomatic Individuality in the Response to Levothyroxine Treatment
Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00664 · Cited by 22
“using a validated thyroid specific QoL questionnaire and following hypothyroid patients with autoimmune thyroiditis, concluded that QoL outcome measures improved but a full recovery was not achieved after 6 months of treatment with LT4 (9).”
MethodInfluentialQuality of life among patients on levothyroxine: A cross-sectional study
Qur‵an, T. A., Bataineh, Z. A., Al-Mistarehi, A.-H. W., Okour, A. M., Yonis, O. B., Khassawneh, A., AbuAwwad, R., & Qura’an, A. A. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.10.030 · Cited by 26
T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity
Wiersinga, W. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.501 · Cited by 21
“The ThyPRO has good cross-cultural validity; the shortened ThyPRO-39, which is now available in many languages, might be preferred [41,85].”
BackgroundInfluentialPhysical performance in newly diagnosed hypothyroidism: a pilot study
Gallo, D., Piantanida, E., Veronesi, G., Lai, A., Sassi, L., Lombardi, V., Masiello, E., Premoli, P., Bianconi, E., Cusini, C., et al. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0661-7 · Cited by 24
“Over the last years, quality-oflife questionnaires have been validated for hypothyroidism [2, 3, 23].”
BackgroundTandon, A., Singh, R., Gupta, S., & Saroja, K. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_165_17 · Cited by 21
“Similar findings were seen in other studies.[14,15] The Colorado study found tiredness, DS, and cold sensitive as the most common hypothyroid symptoms.”
ResultRecker, S., Voigtlaender, R., Viehmann, A., Dunschen, K., Kerp, H., Frank‐Raue, K., Leidig‐Bruckner, G., Graf, D., Lederbogen, S., Dietrich, J. W., et al. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0897-8785 · Cited by 27
“For example in a Danish general population sample (n = 739, average age of 50 years) the baseline Tiredness score was 35 [14].”
BackgroundResultInfluentialSelf-citationRomero-Gómez, B., Guerrero-Alonso, P., Carmona‐Torres, J. M., Pozuelo‐Carrascosa, D. P., Laredo‐Aguilera, J. A., & Cobo‐Cuenca, A. I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123864 · Cited by 25
“Similar to other chronic diseases, nontreated hypothyroidism reduces the HRQOL of patients [22,30].”
BackgroundResultInfluentialHoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2018) · Journal of Thyroid Research · doi:10.1155/2018/3239197 · Cited by 20
Park, S. H., & Hong, S. H. (2018) · Journal of Medical Internet Research · doi:10.2196/11085 · Cited by 20
“Patients with hypothyroidism are treated with the most frequently prescribed drug in the United States, levothyroxine [1], but report poor quality of life despite the treatment [2-4].”
BackgroundCasula, S., Ettleson, M. D., & Bianco, A. C. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.003 · Cited by 21
Taani, M. H., Strath, S. J., Cho, C. C., Ellis, J., & Oh, H. (2022) · Research in Gerontological Nursing · doi:10.3928/19404921-20220408-01 · Cited by 21
Bornikowska, K., Gietka-Czernel, M., Raczkiewicz, D., Glinicki, P., & Zgliczyński, W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225233 · Cited by 17
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
Zhou, N., Velez, M. A., Bachrach, B., Gukasyan, J., Fares, C. M., Cummings, A. L., Lind-Lebuffe, J. P., Akingbemi, W. O., Li, D., Brodrick, P. M., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.009 · Cited by 20
Pajzsmirigyhormon-kezelési szokások Magyarországon.: A THESIS kérdőíves felmérés eredményei
Berta, E., Lengyel, I. M., Hegedűs, L., Papini, E., Perros, P., Negro, R., Attanasio, R., Nagy, V. E., & Bodor, M. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32412 · Cited by 17
“[13] Winther KH, Cramon P, Watt T, et al.”
BackgroundSelf-citationRezaei, S., Abedi, P., Maraghi, E., Hamid, N., & Rashidi, H. (2020) · Thyroid Research · doi:10.1186/s13044-020-00080-z · Cited by 16
Boesen, V. B., Feldt‐Rasmussen, U., Bjørner, J. B., Cramon, P. K., Grøenvold, M., Nygaard, B., Rasmussen, Å. K., Vilsbøll, T., & Watt, T. (2018) · Thyroid · doi:10.1089/thy.2018.0210 · Cited by 19
Self-citationImplementation of thyroid-related patient-reported outcomes in routine clinical practice
Cramon, P. K., Bjørner, J. B., Grøenvold, M., Boesen, V. B., Bonnema, S. J., Hegedűs, L. D., Feldt‐Rasmussen, U., Rasmussen, Å. K., & Watt, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1000682 · Cited by 19
Self-citationMehuys, E., Lapauw, B., T'Sjoen, G. G., Christiaens, T. C., Sutter, A. D., Steurbaut, S., Tongelen, I. V., & Boussery, K. (2023) · Thyroid · doi:10.1089/thy.2023.0066 · Cited by 19
Quality of life after long-term biochemical control of acromegaly
Kimball, A., Dichtel, L. E., Yuen, K. C. J., Woodmansee, W. W., Haines, M. S., Nachtigall, L. B., Swearingen, B., Jones, P. S., Tritos, N. A., Sharpless, J. L., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01224-0 · Cited by 15
Problem gambling during Covid-19
Frisone, F., Alibrandi, A., & Settineri, S. (2020) · Mediterranean Journal of Clinical Psychology · doi:10.6092/2282-1619/mjcp-2457 · Cited by 32
Zahan, A. E. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.192 · Cited by 18
“In the past decades, the importance of involving measurements of HRQoL aspects in the evaluation of thyroid patients has been increasingly recognized (3-8).”
BackgroundAshraf, H., Heydari, M., Shams, M., Zarshenas, M. M., Tavakoli, A., & Sayadi, M. (2022) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2022/5456855 · Cited by 13
“demonstrated that treatment with levothyroxine for six weeks significantly improved the QoL of hypothyroidism patients compared to the general population [33].”
BackgroundHoermann, R., Midgley, J. E. M., Dietrich, J. W., & Larisch, R. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817716401 · Cited by 14
Puy, R. S. D., Postmus, I., Stott, D. J., Blum, M. R., Poortvliet, R. K. E., den Elzen, W. P. J., Peeters, R. P., Munster, B. C. V., Wolffenbuttel, B. H. R., Westendorp, R. G. J., et al. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0285-8 · Cited by 15
Self-citationShepelkevich, A. P., Dydyshka, Y. V., Yurenya, E., Лобашова, В. Л., Attanasio, R., Hegedűs, L. D., Nagy, E. V., Negro, R., Papini, E., & Perros, P. (2021) · Problems of Endocrinology · doi:10.14341/probl12828 · Cited by 14
Self-citationHypothyroidism, comorbidity and health-related quality of life: a population-based study
Wouters, H. J. C. M., Wolffenbuttel, B. H. R., Kobold, A. C. M., Links, T. P., Huls, G. A., & van der Klauw, M. M. (2023) · Endocrine Connections · doi:10.1530/ec-23-0266 · Cited by 17
Predictors of Improvement in Quality of Life When Treating Hypothyroidism
Medici, B. B., la Cour, J. L., Knop, F. K., Krakauer, M., Michaelsson, L. F., Faber, J. O., Watt, T., & Nygaard, B. (2021) · Journal of Thyroid Research · doi:10.1155/2021/5577217 · Cited by 14
Self-citationChartoumpekis, D. V., Ziros, P. G., Habeos, I. G., & Sykiotis, G. P. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.08.021 · Cited by 13
“281 health-related quality of life [53].”
Assessment of Quality of Life Among Patients With Primary Hypothyroidism: A Case-Control Study
Ghamri, R. A., Babaker, R. K., Ezzat, S., Alsaedi, H., Alkhamisi, M., Arbaein, R., Alyahya, R., Fayraq, S., & Alamri, S. (2022) · Cureus · doi:10.7759/cureus.29947 · Cited by 12
“A greater effect of hypothyroidism on the QoL of patients with lower mental health levels has been determined [12] and one of the most prevalent psychiatric parameters affected by hypothyroidism is depression in the elderly [13].”
BackgroundResultHirtz, R., Keesen, A., Hölling, H., Hauffa, B. P., Hinney, A., & Grasemann, C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00454 · Cited by 15
Moncayo, R., & Moncayo, H. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.03.004 · Cited by 16
“The vascular structure is clearly recognized in the 3D mode.”
Patti, M., Christian, R., & Palokas, M. J. (2021) · JBI Evidence Synthesis · doi:10.11124/jbies-20-00043 · Cited by 14
Change in Thyroid Hormone Metabolite Concentrations Across Different Thyroid States
Jongejan, R. M. S., van Velsen, E. F. S., Meima, M. E., Klein, T., van den Berg, S. A. A., Massolt, E. T., Visser, W. E., Peeters, R. P., & de Rijke, Y. B. (2022) · Thyroid · doi:10.1089/thy.2021.0453 · Cited by 12
Tabakoğlu, N. T., & Çelik, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113082 · Cited by 16
“Recently, a health approach that emphasizes improving patients’ quality of life is as important as treating chronic diseases has been adopted [15–17].”
BackgroundApproach to the Patient With Thyroid Cancer: Selection and Management of Candidates for Lobectomy
Robenshtok, E., Bachar, G. Y., & Ritter, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae903 · Cited by 13
Sørensen, J. R., Døssing, H., Watt, T., Cramon, P. K., Hegedűs, L. D., Bonnema, S. J., & Folkestad, L. (2022) · Thyroid · doi:10.1089/thy.2021.0665 · Cited by 12
“An exception was that goiter symptoms remained statistically more prevalent among patients, which is in accordance with persistent symptoms in other thyroid phenotypes such as hypothyroidism (32) and hyperthyroidism (33).”
Self-citationRiis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
Self-citationLarsen, C. B., Winther, K. H., Cramon, P. K., Rasmussen, Å. K., Feldt‐Rasmussen, U., Grøenvold, M., Bjørner, J. B., Hegedűs, L. D., Watt, T., & Bonnema, S. J. (2023) · Thyroid Research · doi:10.1186/s13044-023-00178-0 · Cited by 12
“However, current treatment regimens may be inadequate, as a substantial fraction of patients have persistent symptoms and a reduced health-related quality of life (HRQL) [2–7].”
BackgroundSelf-citationEye symptoms in patients with benign thyroid diseases
Sawicka‐Gutaj, N., Ziółkowska, P., Wojciechowska, K., Shawkat, S., Czarnywojtek, A., Warchol, W. J., Sowiński, J., Szczepanek‐Parulska, E., & Ruchała, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-98232-0 · Cited by 15
Хронічна ішемія мозку у хворих з артеріальною гіпертензією та гіпотиреозом
Kovalenko, O., & Lytvyn, O. (2017) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.13.1.2017.96764 · Cited by 8
Prevalence and predictors of adequate treatment of overt hypothyroidism – a population-based study
Graversen, J. L., Karmisholt, J., Pedersen, I. B., & Carlé, A. (2022) · EXCLI journal · doi:10.17179/excli2021-4291 · Cited by 14
Puga, F., Simões, H., Melo, M., Attanasio, R., Hegedűs, L. D., Nagy, E. V., Papini, E., Perros, P., & Freitas, C. (2022) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ao210050 · Cited by 11
Self-citationSubclinical hypothyroidism: To treat or not to treat?
Simon, C., Weidman-Evans, E., & Allen, S. (2020) · JAAPA · doi:10.1097/01.jaa.0000660120.03250.55 · Cited by 10
Cui, Z., Ding, X., Bian, N., Chang, X., Wang, J., An, Y., Liu, J., & Wang, G. (2022) · International Journal of Endocrinology · doi:10.1155/2022/1918674 · Cited by 9
“Moreover, a prospective cohort study observed that full recovery was not obtained in patients with autoimmune hypothyroidism, despite most aspects improving after 6 months of LT4 therapy [23].”
BackgroundPremawardhana, L. D., Taylor, P. N., Okosieme, O. E., Adlan, M. A., Obuobie, E. K., & Dayan, C. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1282608 · Cited by 6
Martin, M., Subramaniyan, R., Naik, D., Ramamoorthy, L., & Lalthanthuami, H. T. (2023) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_103_23 · Cited by 9
“[11,22] A double‑blind randomized cross‑over trial by Kelderman‑Bolk et al ., revealed that the mean BMI of hypothyroid patients was 29.1 ± 5, which belongs to the overweight category.”
MethodResultInfluentialRomero-Ibarguengoitia, M. E., Garza‐Silva, A., Rivera-Cavazos, A., Morales-Rodríguez, D. P., Peña, O. I. G., Barco-Flores, I. A., Manilla-Muñoz, E., Villarreal-Leal, E., & González‐Cantú, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad175 · Cited by 9
“Previous studies have established that patients with treated hypothyroidism experience an improved quality of life compared to the early stages of the disease [42].”
BackgroundThe Impact of Hypothyroidism on the Quality of Life of Adults in Riyadh, Saudi Arabia
AlAwaji, M. I., & Alhamwy, R. (2023) · Cureus · doi:10.7759/cureus.37636 · Cited by 18
“It has been found that the negative impact of hypothyroidism on QoL is higher in patients with poorer mental health [17], and depression is one of the most common psychiatric characteristics associated with hypothyroidism in elderly people [18].”
BackgroundMethodPrevalence and severity of fatigue in treated hypothyroidism: results of a UK survey
Grixti, L., Fisher, H., Priestley, J., McMullan, C., Woollven, A., Perros, P., Mitchell, A. L., Gan, E. H., & Pearce, S. H. S. (2025) · European Thyroid Journal · doi:10.1530/etj-25-0044 · Cited by 5
Metadata
- Authors
- Winther, K. H., Cramon, P., Watt, T., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Groenvold, M., Rasmussen, Å. K., Hegedüs, L., & Bonnema, S. J.
- Affiliations
- University of Southern Denmark (DK)
- Copenhagen University Hospital (DK)
- Corresponding author
- Winther, Kristian Hillert
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-06-03
- Volume
- 11
- Issue
- 6
- Pages
- e0156925
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4892657
- OpenAlex
- W2410385350
- Cited by
- 152
- References
- 42
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 13 · 2023: 12 · 2022: 21 · 2021: 20 · 2020: 15 · 2019: 15 · 2018: 18 · 2017: 15 · 2016: 3
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-sa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novo Nordisk
- Odense Universitetshospital
- Rigshospitalet
- Syddansk Universitet
- Novo Nordisk Fonden (NNF15OC0014622)
- Forsknings- og Innovationsstyrelsen
- Danish Agency for Science and Higher Education
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- autoimmune hypothyroidism, autoimmune thyroiditis, health-related quality of life, levothyroxine therapy, SF-36, fatigue, vitality, disease-specific quality of life, generic quality of life, treatment outcomes
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Hormones, Humans, Male, Middle Aged, Prospective Studies, Psychometrics, Quality of Life, Surveys and Questionnaires, Thyroiditis, Autoimmune, Thyroxine, Time Factors, Hashimoto Disease, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.